Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
5.65
-0.30 (-5.04%)
Apr 29, 2026, 12:38 PM EDT - Market open
Plus Therapeutics Employees
Plus Therapeutics had 28 employees as of December 31, 2025. The number of employees increased by 7 or 33.33% compared to the previous year.
Employees
28
Change (1Y)
7
Growth (1Y)
33.33%
Revenue / Employee
$186,179
Profits / Employee
-$799,500
Market Cap
38.77M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Werewolf Therapeutics | 39 |
| Mereo BioPharma Group | 39 |
| INmune Bio | 21 |
| RenovoRx | 17 |
| Sensei Biotherapeutics | 15 |
| Atara Biotherapeutics | 14 |
| Rein Therapeutics | 10 |
PSTV News
- 1 day ago - Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 6 days ago - Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - GlobeNewsWire
- 6 days ago - Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 14 days ago - Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution - GlobeNewsWire
- 20 days ago - Plus Therapeutics Appoints Eric J. Daniels, M.D. - GlobeNewsWire
- 21 days ago - Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas - GlobeNewsWire
- 22 days ago - Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption - GlobeNewsWire